The arylpiperazine derivatives \(N\)-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide and \(N\)-benzyl-4-(2-diphenyl)-1-piperazinehexanamide exert a long-lasting inhibition of human serotonin 5-HT\(_7\) receptor binding and cAMP signaling

Patricio Atanes\(^1\), Enza Lacivita\(^2\), Javier Rodríguez\(^1\), José Brea\(^1\), Javier Burgueño\(^3\), José Miguel Vela\(^3\), María Isabel Cadavid\(^1\), María Isabel Loza\(^1\), Marcello Leopoldo\(^{2*}\) & Marián Castro\(^{1*}\)

\(^1\)Biofarma Research Group, Department of Pharmacology, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, Santiago de Compostela, Spain
\(^2\)Dipartimento di Farmacia – Scienze del Farmaco, Università degli Studi di Bari "A. Moro", Bari, Italy
\(^3\)Esteve; Drug Discovery and Preclinical Development, Barcelona, Spain

**Abstract**

We performed a detailed in vitro pharmacological characterization of two arylpiperazine derivatives, compound \(N\)-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide (LP-211) previously identified as a high-affinity brain penetrant ligand for 5-hydroxytryptamine (serotonin) type 7 (5-HT\(_7\)) receptors, and its analog \(N\)-benzyl-4-(2-diphenyl)-1-piperazinehexanamide (MEL-9). Both ligands exhibited competitive displacement of \([\text{H}]\)-SB-269970 radio-ligand binding and insurmountable antagonism of 5-carboxamidotryptamine (5-CT)-stimulated cyclic adenosine monophosphate (cAMP) signaling in human embryonic kidney (HEK293) cells stably expressing human 5-HT\(_7\) receptors. They also inhibited forskolin-stimulated adenylate cyclase activity in 5-HT\(_7\)-expressing HEK293 cells but not in the parental cell line. The compounds elicited long-lasting (at least 24 h) concentration-dependent inhibition of radioligand binding at 5-HT\(_7\)-binding sites in whole-cell radioligand binding assays, after pretreatment of the cells with the compounds and subsequent compound removal. In cAMP assays, pretreatment of cells with the compounds rendered 5-HT\(_7\) receptors unresponsive to 5-CT and also rendered 5-HT\(_7\)-expressing HEK293 cells unresponsive to forskolin. Compound 1-(2-biphenyl)piperazine (RA-7), a known active metabolite of LP-211 present in vivo, was able to partially inhibit 5-HT\(_7\) radioligand binding in a long-lasting irreversible manner. Hence, LP-211 and MEL-9 were identified as high-affinity long-acting inhibitors of human 5-HT\(_7\) receptor binding and function in cell lines. The detailed in vitro characterization of these two pharmacological tools targeting 5-HT\(_7\) receptors may benefit the study of 5-HT\(_7\) receptor function and it may lead to the development of novel selective pharmacological tools with defined functional properties at 5-HT\(_7\) receptors.

**Keywords**

\([\text{H}]\)-SB-269970 binding, arylpiperazine derivative, cAMP signaling, HEK293 cells, insurmountable antagonism, irreversible inhibition, long-lasting inhibition, LP-211, preincubation/washout experiments, Schild analysis, serotonin 5-HT\(_7\) receptors

**Correspondence**

Marián Castro, Molecular Pharmacology Laboratory, Biofarma Research Group. Center for Research in Molecular Medicine and Chronic Diseases (CIMUS). University of Santiago de Compostela. Avda. de Barcelona, s/n, 15782 Santiago de Compostela, Spain. Tel: +39-8818-15457; Fax +39-8818-15403; E-mail: marian.castro@usc.es

*Both Marcello Leopoldo and Marian Castro contributed equally in the role of a Corresponding Author.

**Funding information**

This study was supported by XUNTA de Galicia [Grant 10PXIB203056PR] and Ministerio de Economía y Competitividad (MINECO) [Grant SAF2009-13609-C04-01]. P. Atanes is in receipt of a “María Barbeito” predoctoral contract from XUNTA de Galicia.

Received: 21 May 2013; Revised: 15 September 2013; Accepted: 24 September 2013

**Pharma Res Per, 1 (2), 2013, e00013, doi: 10.1002/prp2.13**

© 2013 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Introduction

The serotonin 5-hydroxytryptamine (serotonin) type 7 (5-HT_7) receptor is a G_i/coupled receptor (Hoyer et al. 2002) expressed in discrete areas of the brain (particularly in hippocampus, thalamus, and hypothalamus) and periphery (Jasper et al. 1997; Regard et al. 2008). Its distribution correlates well with the functions attributed to the receptor in learning/memory, regulation of mood, thermoregulation, nociception or circadian rhythms, among others (Hedlund and Sutcliffe 2004; Leopoldo et al. 2011). The interest in 5-HT_7 receptors as drug target in clinical conditions such as depression, schizophrenia, sleep disorders, migraine, or neuropathic pain (Hedlund 2009; Stahl 2010; Matthys et al. 2011; Meltzer and Massey 2011; Bonaventure et al. 2012; Henigsberg et al. 2012; Cates et al. 2013), together with current efforts aimed to develop the first 5-HT_7-selective positron emission tomography radioligand (Lemoine et al. 2011), warrants investigations of the mechanisms of action of compounds acting at these receptors.

Progress in 5-HT_7 research has been hampered by the lack of selective ligands. However, the recent development and characterization of selective compounds (Pittalà et al. 2007; Brenchat et al. 2009; Leopoldo et al. 2011), combined with molecular biology techniques, is helping unveil the rich 5-HT_7 pharmacology. We have previously developed different series of 4-substituted 1-arylpiperazine derivatives (Perrone et al. 2003; Leopoldo et al. 2004a,b, 2007, 2008). Among these, compound N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide (LP-211) exhibited nanomolar affinity for rat (K_i = 0.58 nmol/L) and human (K_i = 15 nmol/L) 5-HT_7 receptors cloned in cell lines (Leopoldo et al. 2008; Hedlund et al. 2010), and lower affinities for 5-HT_7A (K_i = 188–379 nmol/L) (Leopoldo et al. 2008; Hedlund et al. 2010), D_2 (K_i = 142 nmol/L) (Leopoldo et al. 2008), and for all other human serotonin receptor subtypes and the human serotonin transporter (SERT) (Hedlund et al. 2010). This compound was able to modulate the capsaicin-induced increase in FBJ murine osteosarcoma viral oncogene homolog (Fos)-like immunoreactivity, a marker of cephalic pain, in rat trigeminal nucleus caudalis (Martinez-García et al. 2011). LP-211 has been proposed as a tool for studying the role of 5-HT_7 receptor systems in sleep disorders and in the modulation of emotional and motivational limbic systems (Adriani et al. 2012). In the case of compound N-benzyl-4-(2-diphenyl)-1-piperazinehexanamide (MEL-9), a close structural analog of LP-211, its K_i value at human 5-HT_7 receptors was estimated to be 0.8 nmol/L from experiments in which the compound showed a behavior not compatible with classical competitive binding (Leopoldo et al. 2008). MEL-9 displayed lower affinities for 5-HT_7A and D_2 receptors (K_i = 503 nmol/L and 161 nmol/L, respectively) (Leopoldo et al. 2008). In spite of their interest as selective 5-HT_7 ligands and pharmacological tools, neither of these two compounds has been functionally characterized in detail in terms of 5-HT_7 down-stream signaling in well-controlled in vitro settings such as a cell line.

The development of drugs and novel chemical tools selective and active at 5-HT_7 receptors has important implications for 5-HT_7 receptor research and central nervous system pharmacology and therapy, which justifies the interest in detailed descriptions of their underlying mechanisms of action. Therefore, in this study, we aimed to undertake a detailed pharmacological characterization of the mechanism of action of compound LP-211 and its analog MEL-9, at human 5-HT_7 receptors expressed in human embryonic kidney (HEK293) cells. The results indicate that both compounds behave as long-lasting inhibitors of 5-HT_7 receptors. These ligands may lead to the development of novel selective pharmacological tools with defined functional properties at 5-HT_7 receptors.

Materials and Methods

Reagents

Compounds MEL-9, LP-211, and 1-(2-biphenyl)piperazine (RA-7) were synthesized at the Dipartimento di Farmacia – Scienze del Farmaco, Università degli Studi di Bari “A. Moro” as previously described (Leopoldo et al. 2008; Lacivita et al. 2012). Clozapine, methiothepin mesylate salt (methiothepin), 5-carboxamidotryptamine maleate salt (5-CT), and forskolin were purchased from Sigma-Aldrich Quimica SL (Madrid, Spain). [³H]-SB 269970 ([(2R)-1-[(3-hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-piperidinyl)ethyl]pyrrolidine] (39.9 Ci/nmol) was purchased from PerkinElmer (Madrid, Spain). All radionuclide binding in preincubation/washout experiments; LP-211, N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide; LSD, lysergic acid diethylamide; MEL-9, N-benzyl-4-(2-diphenyl)-1-piperazinehexanamide; RA-7, 1-(2-biphenyl)piperazine; REM, rapid eye movement; SB-269970, (2R)-1-[(3-hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-piperidinyl)ethyl]pyrrolidine; SERT, serotonin transporter; xlog P, prediction of log of octanol/water partition coefficient.
other reagents were purchased from Sigma-Aldrich Química SL (Madrid, Spain), unless otherwise specified.

**Cell culture**

HEK293 cells stably expressing the human 5-HT<sub>7</sub>(a) receptor (HEK-hu5-HT<sub>7</sub>) (at a receptor density of 22 pmol/mg protein) were kindly provided by Laboratorios Esteve (Barcelona, Spain) and have been employed in previous studies (Varin et al. 2010). Cells were grown in culture medium (Dulbecco’s Modified Eagle’s Medium [4.5 g/l glucose]) supplemented with 10% (v/v) fetal bovine serum, 100 U/mL penicillin, 100 mg/mL streptomycin, GlutaMAX<sup>TM</sup>-I (Gibco, Life Technologies S.A., Madrid, Spain), 2 mM L-glutamine, 1 mM sodium pyruvate, and 0.5 mg/ml genetin (G418 sulfate, Gibco), at 37°C in a 5% CO<sub>2</sub> humidified atmosphere.

**Membrane homogenate radioligand binding**

Cell membrane homogenate was prepared as previously described (Varin et al. 2010). Membrane homogenate (5 μg protein/tube) was incubated for 60 min at 37°C in 500 μL of binding buffer (50 mmol/L Tris-HCl pH 7.4, 4 mmol/L MgCl<sub>2</sub>, 1 mmol/L ascorbic acid and 0.1 mmol/L pargyline) containing [3H]-SB-269970 as radioligand. Nonspecific binding was determined in the presence of 25 μmol/L clozapine. 5-HT<sub>7</sub> receptor density (B<sub>max</sub> = 21.80 ± 0.76 pmol/mg prot.) and affinity (K<sub>d</sub>) of the radioligand for the receptors were determined in saturation binding experiments with concentrations of the radioligand ranging from 0.03 to 30 nmol/L. The effect of the compounds under study, at the concentrations indicated for 30 min at 37°C, was stopped, as previously described for membrane homogenate radioligand binding assays.

**Whole-cell radioligand binding (preincubation/washout experiments)**

To determine the effects of the compounds on [3H]-SB-269970 binding following removal of the compounds, intact cells were detached and harvested, as described for whole-cell radioligand binding assays in the presence of the compounds, and then preincubated in HEPES buffer (10 × 10<sup>5</sup> cells/mL) in the absence (control) or presence of the compounds under study, at the concentrations indicated for 30 min at 37°C under gentle agitation. The cell suspension was centrifuged at 330g for 6 min, the cell pellet was washed three times for 10 min in HEPES buffer at 37°C, and the cells were immediately resuspended in HEPES buffer for [3H]-SB-269970 binding assays. For this purpose, 50,000 cells/tube were incubated in assay tubes containing 2 nmol/L [3H]-SB-269970 in 500 μL HEPES buffer in the absence or presence of 25 μmol/L clozapine to determine the total and nonspecific binding, respectively. After incubation for 30 min at 37°C, the assay was stopped, as previously described. To determine the time course of recovery of the specific binding of [3H]-SB-269970 after removal of the compounds, cells handled under sterile conditions were incubated with the compounds, as indicated above. After compound washout, cells were incubated for different times (t = 0, 1, 3, 6, and 24 h) at 37°C in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12-GlutaMAX<sup>TM</sup> (Gibco) supplemented with 100 U/mL penicillin and 100 mg/mL streptomycin, under sterile conditions, prior to being subjected to binding assays to determine the total and nonspecific [3H]-SB-269970 binding, as described above.
cAMP assays (assays in the presence of the compounds)

cAMP levels were quantified using the homogeneous time-resolved fluorescence (HTRF)-based cAMP dynamic kit (Cisbio, Bioassays, Codolet, France). Twenty-four hours before the assay, HEK-hu5-HT7 cells were plated at a density of 8000 cells/well in Opti-MEM medium (Invitrogen, Life Technologies S.A.) in white polystyrene, tissue-culture treated, half-area Corning 96 well plates pretreated with poly-D-lysine. To measure agonist effects, cells were incubated in cAMP assay buffer (Opti-MEM, 500 μmol/L 3-isobutyl-1-methylxanthine [IBMX]) for 15 min at 37°C prior to the addition of the compounds and further incubation for 15 min. The antagonist effect of the compounds was evaluated in the presence of 5-CT (at the indicated concentration) by constructing concentration–response curves. Cells were incubated in the absence (control) or presence of increasing concentrations (from 100 pmol/L to 10 μmol/L) of the compounds in assay buffer for 15 min at 37°C prior to the addition of the agonist and further incubation for 15 min. For Schild analysis, concentration–response curves were constructed for 5-CT in the absence (control) or presence of the compounds at the concentrations indicated. Cells were incubated with the compounds in assay buffer for 15 min at 37°C prior to addition of increasing concentrations (from 100 pmol/L to 10 μmol/L) of 5-CT and further incubation for 15 min. In all cases, basal cAMP levels were determined in control wells in the absence of agonist. The effects of the compounds on forskolin-stimulated adenylate cyclase activity were evaluated either at a single concentration (parental HEK293 cells) or by using concentration–response curves (HEK-hu5-HT7 cells). Cells were incubated in the absence (control) or presence of the compounds, at the concentrations indicated, in assay buffer for 15 min at 37°C prior to the addition of forskolin and further incubation for 15 min. Basal cAMP levels were determined in control wells in the absence of forskolin. After proceeding with the subsequent assay steps according to the manufacturer’s protocol, the fluorescence emission intensity ratio at 665/620 nm wavelength was measured in an Ultra Evolution 384 microplate reader (TECAN, Männedorf, Switzerland).

cAMP assays (preincubation/washout experiments)

To determine the effects of the compounds on 5-CT- or forskolin-stimulated cAMP levels following removal of the compounds, cells plated as previously described for cAMP assays 6 were preincubated in the absence (control) or presence of increasing concentrations (from 100 pmol/L to 10 μmol/L) of the compounds in cAMP assay buffer for 30 min at 37°C. The cells were then washed three times for 10 min in Opti-MEM at 37°C and incubated in cAMP assay buffer with 10 μmol/L 5-CT for 30 min at 37°C, or with 10 μmol/L forskolin for 15 min at 37°C. Basal cAMP levels were determined in control wells in the absence of 5-CT or forskolin in each case. After proceeding with the subsequent assay steps according to the manufacturer’s protocol, fluorescence was measured as previously described.

Data analysis

The data were analyzed using GraphPad Prism software v4.0 (GraphPad Software Inc., San Diego, CA). Receptor density (Bmax) and the dissociation constant (Kd) of the radioligand were determined by nonlinear regression curve fitting of saturation binding binding curves to a one-site binding (hyperbola) model. The inhibitory dissociation constants (Ki) for the compounds under study were calculated using competition binding experiments, according to the Cheng and Prusoff equation: Ki = IC50/[1 + [L]/Ki], where IC50 is the concentration of the unlabelled compounds leading to half-maximal inhibition of the specific binding, [L] is the concentration of the radioligand used in the assay and Ki is the dissociation constant of the radioligand determined by nonlinear regression curve fitting of saturation binding curves to a one-site binding (hyperbola) model (Kd = 1.53 ± 0.16 nmol/L in membrane homogenate assays; Kd = 1.49 ± 0.18 nmol/L in whole-cell assays). The IC50 values were determined by nonlinear regression curve fitting to sigmoidal dose–response or sigmoidal dose–response (variable slope) models, as indicated. Specific binding was expressed as the percent of specific [3H]-SB-269970 binding in control conditions. 5-CT potency (EC50) and efficacy (maximal response [Emax]) and antagonist potency (IC50) of the compounds in cAMP assays were calculated by fitting the data to a sigmoidal dose–response model. IC50 denotes the concentration of compound that causes half-maximal inhibition of cAMP production stimulated by 5-CT or forskolin, and IC50, irrev denotes the potency of the compounds as irreversible inhibitors of 5-HT7-mediated cAMP signaling or whole-cell 5-HT7 radioligand binding in preincubation/washout experiments. Results are expressed as the mean values ± SEM from the number of independent experiments indicated. Prediction of log of octanol/water partition coefficient (xlog P) values were retrieved from ZINC database (http://zinc.docking.org/) (Irwin et al. 2012).

Results

Compound LP-211 and its analog MEL-9 (Fig. 1) completely displaced the binding of [3H]-SB-269970 to membrane homogenates of HEK293 cells stably expressing
the human 5-HT<sub>7</sub> receptor (HEK-hu5-HT<sub>7</sub>) (Fig. 2), which is compatible with competitive binding. The compounds exhibited affinities in the nanomolar range for human 5-HT<sub>7</sub> receptors that are consistent with previous findings (Leopoldo et al. 2008; Hedlund et al. 2010), and the Hill slopes (n<sub>H</sub>) were close to unity. The affinity constant (K<sub>i,p</sub>) and n<sub>H</sub> values for the compounds and methiothepin, included in the experiments as a reference compound, are shown in Table 1.

For characterization of the efficacy profile of the compounds, we evaluated their effects on the human 5-HT<sub>7</sub>-mediated cAMP signaling pathway in HEK-hu5-HT<sub>7</sub> cells. The compounds did not elicit any detectable increase in cAMP levels in the cells over the range of concentrations assayed (from 100 pmol/L to 10 μmol/L), while the 5-HT<sub>1&7</sub> receptor-selective agonist 5-CT (100 nmol/L), included in the experiments as a reference agonist, increased cAMP levels by up to more than 50 times above basal levels under the same conditions (data not shown). Moreover, the compounds completely antagonized the cAMP signaling stimulated by 1 μmol/L 5-CT, in a concentration-dependent manner, with IC<sub>50</sub> values close to their affinities for 5-HT<sub>7</sub> receptors (IC<sub>50</sub> = 27.84 ± 6.72 nmol/L and 20.91 ± 5.72 nmol/L, for MEL-9 and LP-211, respectively, n = 3). The compounds inhibited with the same potency the cAMP response stimulated by 5 nmol/L and 1 μmol/L 5-CT (Fig. 3), two concentrations of the agonist that differ by ~200 times (ranging from 0.3 times lower to 69 times higher than the EC<sub>50</sub> value), therefore showing a behavior not consistent with classical competitive antagonism (Kenakin 2009).

Concentration–response curves for cAMP production by 5-CT (10 nmol/L–10 μmol/L) in the absence or presence of different concentrations (10 nmol/L, 100 nmol/L or 1 μmol/L) of the antagonists (Schild analysis) revealed an insurmountable antagonistic behavior for both
compounds, which produced a rightward shift of the 5-CT concentration–response curves, while reducing the maximal 5-CT response in a concentration-dependent manner until it was completely suppressed (Fig. 4). The EC50 values for 5-CT and the percent decrease in the maximal 5-CT response in the absence or presence of different concentrations of the compounds are shown in Table 2.

To analyze the mechanism of the observed insurmountable antagonism, we investigated the reversible or irreversible behavior of the antagonistic effect using concentration–response curves. MEL-9 and LP-211 produced a rightward shift of the 5-CT concentration–response curves, while reducing the maximal 5-CT response in a concentration-dependent manner until it was completely suppressed (Fig. 4). The EC50 values for 5-CT and the percent decrease in the maximal 5-CT response in the absence or presence of different concentrations of the compounds are shown in Table 2.

Table 1. Affinity of MEL-9, LP-211 and methiothepin for human 5-HT7 receptors expressed in HEK293 cells from [3H]-SB-269970 competitive binding experiments.

| Compound  | 5-HT7 affinity (membrane homogenate radioligand binding) | 5-HT7 affinity (whole-cell radioligand binding) |
|-----------|----------------------------------------------------------|-------------------------------------------------|
|           | K_i (nmol/L) | pK_i | n_H | K_i (nmol/L) | pK_i |
| MEL-9     | 16.60 ± 0.99 | 7.78 | 1.34 ± 0.14 | 13.77 ± 0.24 | 7.86 |
| LP-211    | 22.52 ± 3.60 | 7.65 | 1 | 19.01 ± 0.14 | 7.72 |
| Methiothepin | 2.31 ± 0.02 | 8.64 | 1 | 2.51 ± 0.73 | 8.62 |

The data are the mean values ± SEM from three independent experiments performed in duplicate. MEL-9, N-benzyl-4-(2-diphenyl)-1-piperazinehexanamide; LP-211, N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide; HEK293, human embryonic kidney cells; 5-HT7, 5-hydroxytryptamine (serotonin) type 7 receptor; [3H]-SB-269970, (2R)-1-[(3-hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-piperidinyl)ethyl]pyrrolidine.

Figure 3. Concentration–response curves for MEL-9 and LP-211 on 5 nmol/L or 1 μmol/L 5-CT-stimulated cAMP production in HEK-hu5-HT7 cells. Cells were preincubated in the absence (control) or presence of the compounds at different concentrations (100 pmol/L–10 μmol/L) for 15 min prior to the addition of 5 nmol/L or 1 μmol/L 5-CT and incubation for 15 min. Basal values were subtracted from 5-CT-stimulated values and expressed as percent of the control 5-CT response. 5 nmol/L 5-CT elicited a cAMP response over basal equal to 44.3 ± 1.6% of the response elicited by 1 μmol/L 5-CT. Data are the mean values ± SEM from three independent experiments performed in triplicate.

Figure 4. Schild analysis for the antagonism of 5-CT-stimulated cAMP signaling by MEL-9 and LP-211 in HEK-hu5-HT7 cells. Concentration–response curves for cAMP production stimulated by 5-CT in the absence (control) or presence of 10 nmol/L, 100 nmol/L or 1 μmol/L of MEL-9 (A) or LP-211 (B). Cells were preincubated with the compounds for 15 min prior to the addition of 5-CT and incubation for 15 min. Basal values were subtracted from 5-CT-stimulated values and expressed as percent of the control maximal 5-CT response. Data are the mean values ± SEM from three independent experiments performed in duplicate.
irreversible nature of the action of the compounds at the 5-HT7-mediated cAMP pathway by using preincubation/washout experiments. HEK-hu5-HT7 cells were treated with no drug (control) or with increasing concentrations of MEL-9 or LP-211 for 30 min before removing the compounds by extensive washout and assessment of the cAMP production stimulated by 5-CT at a concentration of 10 µmol/L (i.e., 690 times higher than the EC50). Both compounds induced complete loss of 5-CT-stimulated cAMP signaling (Fig. 5), and the potency for this irreversible inhibition (IC50, irrev) was in the nanomolar range (Table 3). This supports an irreversible or pseudo-irreversible mechanism of antagonism by both compounds in the cAMP pathway.

In light of our previous results, we investigated a possible irreversible or pseudo-irreversible interaction between the compounds and the human 5-HT7 receptor. MEL-9 and LP-211 fully displaced the binding of [3H]-SB-269970 to 5-HT7 receptors in competition binding experiments performed with whole-HEK-hu5-HT7 cells, exhibiting affinities in the range of those obtained in cell membrane homogenate binding assays (Table 1). The same was observed for methiothepin, included in the experiments as a reference compound (Table 1). Preincubation of the cells with increasing concentrations (100 pmol/L–10 µmol/L) of MEL-9 or LP-211, followed by washout of the compounds and subsequent [3H]-SB-269970 radioligand binding to the intact cells resulted in a complete concentration-dependent reduction in [3H]-SB-269970 specific binding. Preincubation of the cells with 1 µmol/L methiothepin also led to the complete loss of [3H]-SB-269970 specific binding, expressed as percent of the [3H]-SB-269970 specific binding in cells preincubated in the absence of compound (control) = −3.27 ± 1.06%, n = 5). [3H]-SB-269970 specific binding in cells preincubated with 10 µmol/L clozapine was, however, 77.74 ± 11.57% (n = 5) of that in cells preincubated in the absence of compound (control) (Fig. 6). These results indicate irreversible inhibition of binding at 5-HT7 binding sites by the compounds,

### Table 2. Schild analysis for the antagonism of 5-CT-stimulated cAMP signaling by MEL-9 and LP-211 in HEK-hu5-HT7 cells.

| [Compound] | MEL-9 | | | LP-211 | |
| --- | --- | --- | --- | --- | |
| | 5-CT EC50 (nmol/L) | 5-CT Emax (% reduction) | 5-CT EC50 (nmol/L) | 5-CT Emax (% reduction) | |
| Control (no compound) | 13.34 ± 3.00 | 0 | 13.34 ± 3.00 | 0 | |
| 10 nmol/L | 13.67 ± 1.70 | 37.10 ± 0.47* | 12.24 ± 5.75 | 58.97 ± 16.42** | |
| 100 nmol/L | 48.21 ± 6.40 | 96.02 ± 2.15*** | 134.7 ± 17.2 | 89.17 ± 7.31*** | |
| 1 µmol/L | n.d. | 101.6 ± 3.14** | n.d. | 93.17 ± 3.87** | |

The table shows the EC50 of 5-CT and the percent reduction in Emax for each concentration of the compounds studied. Data are the mean values ± SEM from three independent experiments performed in duplicate. (*P < 0.05, **P < 0.01, relative to control; One-way ANOVA and Dunnett’s Multiple Comparison Test). n.d., not determined; MEL-9, N-benzyl-4-(2-diphenyl)-1-piperazinehexanamide; LP-211, N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide; 5-CT, 5-carboxamidotryptamine; Emax, maximal response.

![Figure 5. Concentration-response curves for the inhibition of 10 µmol/L 5-CT-stimulated cAMP production by MEL-9 and LP-211 in HEK-hu5-HT7 cells in preincubation/washout experiments. Cells were preincubated in the absence (control) or presence of the compounds at increasing concentrations (ranging from 100 pmol/L to 10 µmol/L) for 30 min. After a compound washout procedure (see Materials and Methods), the cells were stimulated with 10 µmol/L 5-CT for 30 min. Basal values were subtracted from 5-CT-stimulated values and expressed as percent of the control 5-CT response. Data are the mean values ± SEM from three independent experiments performed in triplicate.](image)
parallel to the observed inhibition of the cAMP signaling. The potency of the compounds as irreversible inhibitors of 5-HT7 radioligand binding observed in these experiments, expressed as the concentration of compound in the preincubation step that reduces the [3H]-SB-269970 specific binding by 50% in intact cells following removal of the compounds (IC50, irrev), is shown in Table 3.

Inhibition of forskolin-stimulated adenylate cyclase activity by 5-HT7 antagonists was previously reported in transfected cell lines (Klein and Teitler 2011). We investigated a possible effect of MEL-9 and LP-211 on forskolin-stimulated adenylate cyclase activity. Both MEL-9 and LP-211 fully inhibited the 10 μmol/L forskolin-stimulated cAMP production in HEK-hu5-HT7 cells, in a concentration-dependent manner, when forskolin was assayed in the continuous presence of the compounds (Fig. 7A and B). The compounds showed no effect on forskolin-stimulated cAMP production in the parental cell line (Fig. 7A and B, inset). The potencies of the compounds as inhibitors of forskolin-stimulated adenylate cyclase activity were in the range of their affinities for 5-HT7 receptors (IC50 = 19.33 ± 8.18 nmol/L and 60.71 ± 0.48 nmol/L, for MEL-9 and LP-211, respectively).

Moreover, washout of the compounds for 30 min prior to stimulation of the cells with forskolin did not lead to recovery of the forskolin-stimulation of adenylate cyclase activity, but to long-lasting concentration-dependent inhibition of forskolin effects (Fig. 7C and D). The potency of the compounds as irreversible inhibitors of forskolin-stimulated adenylate cyclase activity observed in these experiments, expressed as the concentration of compound in the preincubation step that reduces the forskolin-stimulation of adenylate cyclase to 50% following removal of the compounds, was IC50, irrev = 11.17 ± 3.25 nmol/L and 13.95 ± 3.93 nmol/L, for MEL-9 and LP-211, respectively (n = 3).

Finally, we determined the time course of recovery of specific binding of [3H]-SB-269970 to 5-HT7 receptors after removal of the compounds. Whole-cell radioligand binding assays performed in HEK-hu5-HT7 cells at different times after preincubation of the cells with the compounds at a maximal inhibitory concentration (10 μmol/L) and subsequent removal of the compounds revealed long-lasting inhibition of [3H]-SB-269970 binding to 5-HT7 receptors by both compounds, which did not recover after 24 h (Fig. 8).

In a recent work from our group, we investigated the agonist or antagonist action of a set of unsubstituted 1-(biphenyl)piperazine derivatives at 5-HT7 receptors (Lacivita et al. 2012). The study revealed that compound RA-7 (Fig. 1) was a high-affinity receptor 5-HT7 antagonist in HeLa cells expressing the receptor (Lacivita et al. 2012). This compound attracted our attention while performing this study because disposition studies in mice revealed that LP-211 undergoes N-dealkylation to RA-7 (Hedlund et al. 2010). Therefore, we aimed to investigate the possible contribution of the RA-7 moiety to the long-lasting irreversible inhibition of 5-HT7 binding sites by MEL-9 and LP-211. RA-7 (10 μmol/L) fully displaced the binding of [3H]-SB-269970 to 5-HT7 receptors in competitive binding experiments performed in whole-HEK-hu5-HT7 cells ([3H]-SB-269970 specific binding (percent of control) = 0.64 ± 0.44%, n = 3), consistent with the previously reported affinity of RA-7 at human 5-HT7 receptors (Hedlund et al. 2010). Preincubation of HEK-hu5-HT7 cells for 30 min at 37°C with 10 μmol/L RA-7 and subsequent compound washout led to inhibition of the specific binding of [3H]-SB-269970 to 5-HT7 receptors of 54.76 ± 5.15% at time t = 0 (Fig. 8); this was significantly lower than the reduction of 97.20 ± 0.23% and 95.03 ± 0.47% achieved by MEL-9 and LP-211 at equimolar concentrations, respectively (P < 0.001, One-way analysis of variance (ANOVA) and Bonferroni’s Multiple Comparison Test). However, and similar to what was observed for MEL-9 and LP-211, the partial inhibition of [3H]-SB-269970 binding to 5-HT7 receptors elicited by RA-7 was also long-lasting (it lasted for at least 24 h) (Fig. 8). The results indicate the contribution of the
N-phenylmethyl-hexenamide moiety to conferring the compounds with the capacity to inhibit the 5-HT7 binding in the long term.

Discussion

The $K_i$ value of LP-211 for human 5-HT7 receptors obtained in this study confirms our previous reports (Hedlund et al. 2010). In the case of MEL-9, we observed full displacement of $[^3H]$-SB-269970 binding in this study as well as of $[^3H]$-LSD (lysergic acid diethylamide) binding ($K_i = 37.92 \pm 11.30 \text{nmol/L}$, $n = 3$, $n_{HF} = 1.11 \pm 0.19$) (data not shown) in membrane homogenates of HEK-hu5-HT7 cells. The difference between the present results and those previously reported for MEL-9 (Leopoldo et al. 2008) may be due to the different cell lines or binding protocols used in each case. The reported affinities of MEL-9 for 5-HT1A and D2 receptors were 9.7-fold and 30-fold lower, respectively, than its affinity for 5-HT7 receptors obtained in our study (Leopoldo et al. 2008).

On the other hand, SB-269970 is considered to date the standard selective 5-HT7 antagonist and a prototype 5-HT7 radioligand (Hagan et al. 2000; Thomas et al. 2000). SB-269970 displays a 50-fold selectivity versus 5-htr1 receptors, a receptor subtype reported not to be endogenously expressed at significant levels in HEK293 cells (Atwood et al. 2011), and over 100-fold selectivity versus other 5-HT receptors, dopaminergic D2 or D3 receptors, and adrenergic alpha1b receptors (Lovell et al. 2000). Considering the affinity profile of the ligands used in this study, the effects of MEL-9 and LP-211 on the $[^3H]$-SB-269970 binding appear to originate from their specific interaction with 5-HT7 receptors.

MEL-9 and LP-211 behaved as irreversible or pseudo-irreversible inhibitors of 5-HT7-binding sites in preincubation/washout experiments. Direct assessment of whether the compounds remain irreversibly bound to the receptor and whether the long-lasting inhibition of binding sites persists after compound dissociation requires a labeled form of the compounds not available to us at this stage. Methiothepin, a so-called “inactivating antagonist” of 5-HT7 receptors (Smith et al. 2006), at the concentration of 1 $\mu$mol/L (~270 times its $K_i$ at human 5-HT7 receptors) also completely inhibit 5-HT7-binding sites under our experimental conditions, while the $[^3H]$-SB-269970 specific binding in cells preincubated with the competitive 5-HT7 antagonist clozapine at the concentration of 10 $\mu$mol/L (~500 times its $K_i$ at human 5-HT7 receptors) was preserved to 78% of control. This fact provides compelling evidence that any residual compound remaining after insufficient washing does not mediate the inhibitory effects of MEL-9 or LP-211. The same reasoning may apply to compound RA-7, which caused a decrease of ~50% in the $[^3H]$-SB-269970 specific binding on preincubation at a concentration equimolar to that of MEL-9 and LP-211. Furthermore, considering that the affinity of RA-7 for 5-HT7 receptors has been reported to be higher than that of MEL-9 and LP-211 (Hedlund et al. 2010), receptor occupancy by itself is not sufficient to explain the efficacy of the compounds inhibiting $[^3H]$-SB-269970 binding.

Incubation of intact cells with agonists often results in internalization of G protein-coupled receptors (GPCR)
away from the plasma membrane (Moore et al. 2007). GPCR internalization has been reported to be dissociated from signaling for certain GPCR ligands (Gray and Roth 2001; Sneddon et al. 2004). Hence, the loss of [3H]-SB-269970 binding in intact cells following preincubation with MEL-9 and LP-211 may be attributed to receptor internalization, even in the absence of cAMP signaling elicited by the compounds. Hydrophobic radioligands such as [125I]-iodopindolol (xlog P = 2.99) and [3H]-mesulergine (xlog P = 1.80) successfully labeled beta-adrenergic and 5-HT7 receptors, respectively, both at the cell surface and within endocytic vesicles in intact cells (Reynolds and Molinoff 1986; Andressen et al. 2006). On the basis of the lipophilicity of [3H]-SB-269970 (xlog P = 2.59), we would expect this radioligand to label both cell surface and internalized 5-HT7 receptors in equilibrium binding assays with intact cells. This precludes receptor internalization as a possible explanation for the loss of radioligand binding following preincubation of intact cells with the compounds under study. Receptor downregulation, that is, a reduction in the total number of receptors, generally requires repeated or prolonged (typically for several hours) activation of the receptors (Tsao and von Zastrow 2000), and it does not usually lead to the complete abolition of receptor binding. Downregulation of the 5-HT7 receptor was not observed in HEK293 or Caco-2 cells after treatment with agonists or antagonists for periods longer than 30 min, even under conditions that led to receptor desensitization (Krobert et al. 2006; Iceta et al. 2009). Therefore, it appears unlikely that receptor downregulation accounts for the complete abolition of [3H]-SB-269970 binding observed in this study.

The observed inhibition of the 5-CT-stimulated cAMP signaling by the compounds was unexpected, particularly for LP-211, which has been extensively studied to date.

Figure 7. Effect of compounds MEL-9 and LP-211 on cAMP signaling stimulated by forskolin in HEK-hu5-HT7 cells. (A, B) Concentration–response curves for MEL-9 (A) and LP-211 (B) on 10 μmol/L forskolin-stimulated cAMP production. Cells were preincubated in the absence (control) or presence of the compounds at different concentrations (100 pmol/L – 10 μmol/L) for 15 min prior to the addition of 10 μmol/L forskolin and incubation for 15 min. Basal values were subtracted from forskolin-stimulated values and expressed as percent of the control forskolin response. Data are the mean values ± SEM from three independent experiments performed in triplicate. (A, B Inset) Lack of effect of 1 μmol/L or 10 μmol/L MEL-9 (A, Inset) and 1 μmol/L or 10 μmol/L LP-211 (B, Inset) on forskolin-stimulated cAMP production in parental HEK293 cells. (C, D) Concentration–response curves for the inhibition of 10 μmol/L forskolin-stimulated cAMP production by MEL-9 (C) and LP-211 (D) in HEK-hu5-HT7 cells in preincubation/washout experiments. Cells were preincubated in the absence (control) or presence of the compounds at increasing concentrations (ranging from 100 pmol/L to 10 μmol/L) for 30 min. After a compound washout procedure (see Materials and Methods), the cells were stimulated with 10 μmol/L forskolin for 15 min. Basal values were subtracted from forskolin-stimulated values and expressed as percent of the control forskolin response. Data are the mean values ± SEM from three independent experiments performed in triplicate.

© 2013 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
and to which 5-HT7 agonist activity has been attributed in both in vivo and in vivo studies. Hence, LP-211 elicited relaxation of substance P-induced contraction in isolated guinea pig ileum (Leopoldo et al. 2008), induced hypothermia in wild type but not in 5-HT7 knock-out mice (Hedlund et al. 2010), and it reverted long-term synaptic depression induced by metabotropic glutamate receptors in mouse hippocampal slices (Costa et al. 2012). These effects are consistent with activation of 5-HT7 receptors by LP-211. Nevertheless, LP-211 exerted antianxiety-like effects in mice, similar to those described for the 5-HT7 receptor agonist SB-269970 (Adriani et al. 2012). Full interpretation of these studies would require a better understanding of how 5-HT7 receptor modulation in vivo contributes to the observed effects through direct versus indirect mechanisms. In particular, the consequences of 5-HT7 receptor activation on 5-HT release and serotonergic neural activity may depend on endogenous 5-HT levels (Matthys et al. 2011).

One possible explanation for the irreversible inhibition of the 5-HT7-mediated cAMP pathway by both compounds is that preincubation with the compounds leads to desensitization of 5-HT7 receptors. This should involve a cAMP-independent mechanism, taking into account the lack of cAMP stimulation elicited by the compounds. Recent studies reported desensitization of 5-HT7-mediated adenylyl cyclase activity in membranes from HEK293 cells through a protein kinase A-independent mechanism, after preincubation of the intact cells for 1 h with SB-269970 (Krobert et al. 2006). SB-269970 also elicited functional desensitization of 5-HT7 receptors in acute administration in vivo (Tokarski et al. 2012). However, the mechanism responsible for the reduction in 5-HT7 agonist-mediated signaling by SB-269970 appears to differ from that operating in the case of MEL-9 and LP-211. First, the reduction did not achieve 100% of the agonist signal in either of the two studies mentioned, and second, contrary to what we observed, desensitization did not occur in parallel to the loss of 5-HT7-binding sites. 5-HT7 receptors have shown characteristics consistent with a model in which an inactive conformational state of the receptor is tightly associated with G protein, independent of agonist binding (Bruheim et al. 2003; Andressen et al. 2006). Therefore, a possible explanation for the inhibitory effects of the compounds on 5-HT7-mediated cAMP signaling is that the compounds irreversibly stabilize this receptor conformation.

The inhibition of forskolin-stimulated adenylyl cyclase activity by MEL-9 and LP-211 specifically in HEK-hu5-HT7 cells and not in the parental cell line reinforces the idea that the effects are due to specific interactions of the compounds with 5-HT7 receptors, ruling out nonspecific effects or a direct interaction with the adenylyl cyclase enzyme as mechanisms responsible for the effect. This inhibition was also observed in preincubation/washout experiments, as expected for the so-called 5-HT7 “inactivating antagonists” (Toohey et al. 2009). 5-HT7 pre-associated signaling complexes may include receptor, G protein and adenylyl cyclase (Bruheim et al. 2003). By interacting with the receptor, the “inactivating” compounds may alter the Gα/adenylate cyclase interaction in a way that persistently hinders the action of forskolin on adenylyl cyclase. Another possible explanation for this effect of the compounds is that they might act as 5-HT7-biased agonists that activate Gα signaling leading to inhibition of forskolin-stimulated cAMP accumulation. However, this seems improbable as Gα-coupling was not reported for this receptor and this mechanism was ruled out both for 5-HT7 “inactivating antagonists” and competitive antagonists by using pertussis toxin (Toohey et al. 2009; Klein and Teitler 2011).

In conclusion, the results allow us to define MEL-9 and LP-211 as irreversible inhibitors of 5-HT7 receptors, being the first report of arylpiperazine derivatives as long-lasting inhibitors of 5-HT7 receptors. Our data are consistent with previous observations of irreversible “inactivation” of 5-HT7 receptors by certain multitarget drugs (Smith et al. 2006; Toohey et al. 2009). Overall, the present results open up new perspectives on the study of 5-HT7 receptors. First, to the best of our knowledge, LP-211 and MEL-9 are the first selective 5-HT7 receptor long-lasting inhibitors to be available. Second, the different profile
exhibited by LP-211 and MEL-9 as compared to RA-7 suggests that the feature of irreversible or pseudo-irreversible inhibition of 5-HT7 binding sites is structure-dependent. Third, as LP-211 has displayed a behavior in 5-HT7 receptor-expressing HEK-293 cells different to that shown in other systems ex vivo and in vivo (i.e., antagonism vs. agonism), questions raise about interpretation of the data obtained by using LP-211. Addressing the above issues will be extremely useful for elucidating the physiological significance of the 5-HT7 receptor.

Disclosures
None declared.

References
Adriani W, Travaglini D, Lacivita E, Saso L, Leopoldo M, Laviola G (2012). Modulatory effects of two novel agonists for serotonin receptor 7 on emotion, motivation and circadian rhythm profiles in mice. Neuropharmacology 62: 833–842.

Andressen KW, Norum JH, Levy FO, Krobert KA (2006). Activation of adenylyl cyclase by endogenous G(s)-coupled receptors in human embryonic kidney 293 cells is attenuated by 5-HT7 receptor expression. Mol Pharmacol 69: 207–215.

Atwood BK, Lopez J, Wager-Miller J, Mackie K, Straiker A (2011). Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis. BMC Genomics 12: 14.

Bonaventure P, Dugovic C, Kramer M, De Boer P, Singh J, Wilson S, et al. (2012). Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder. J Pharmacol Exp Ther 342: 429–440.

Bruheim S, Krobert KA, Andressen KW, Levy FO (2003). Unaltered agonist potency upon inducible 5-HT7(a) but not 5-HT7(b) receptor expression indicates agonist-independent association of 5-HT7(a) receptor and Gs. Receptors Channels 9: 107–116.

Cates LN, Roberts AJ, Huitron-Resendiz S, Hedlund PB (2013). Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype. Neuropharmacology 70: 211–217.

Costa L, Spatuzza M, D’Antoni S, Bonaccorso CM, Trovato C, Musumeci SA, et al. (2012). Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome. Biol Psychiatry 72: 924–933.

Gray JA, Roth BL (2001). Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists. Brain Res Bull 56: 441–451.

Hagan JJ, Price GW, Jeffrey P, Deeks NJ, Stean T, Piper D, et al. (2000). Characterization of SB-269970-A, a selective 5-HT7 receptor antagonist. Br J Pharmacol 130: 539–548.

Hedlund PB (2009). The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology 206: 345–354.

Hedlund PB, Sutcliffe JG (2004). Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci 25: 481–486.

Hedlund PB, Leopoldo M, Caccia S, Sarkisyan G, Fracasso C, Martelli G, et al. (2010). LP-211 is a brain penetrant selective agonist for the serotonin 5-HT7 receptor. Neurosci Lett 481: 12–16.

Henigsberg N, Mahabelshwarkar AR, Jacobsen P, Chen Y, Thase ME (2012). A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 73: 953–959.

Hoyer D, Hannon JP, Martin GR (2002). Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71: 533–554.

Iceta R, Mesonero JE, Aramayona J, Alcalde AI (2009). Expression of 5-HT1A and 5-HT7 receptors in Caco-2 cells and their role in the regulation of serotonin transporter activity. J Physiol Pharmacol 60: 157–164.

Irwin JJ, Sterling T, Mysinger MM, Bolstald ES, Coleman RG (2012). ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 52:1757–1768. doi: 10.1021/ci3001277

Jasper JR, Kosaka A, To ZP, Chang DJ, Eglen RM (1997). Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b). Br J Pharmacol 122: 126–132.

Kenakin TP (2009). A pharmacology primer. theory, applications, and methods. 3rd ed. Elsevier Academic Press. San Diego, CA.

Klein MT, Teitler M (2011). Antagonist interaction with the human 5-HT7 receptor mediates the rapid and potent inhibition of non-G-protein-stimulated adenylate cyclase activity: a novel GPCR effect. Br J Pharmacol 162: 1843–1854.

Krobert KA, Andressen KW, Levy FO (2006). Heterologous desensitization is evoked by both agonist and antagonist stimulation of the human 5-HT7 serotonin receptor. Eur J Pharmacol 532: 1–10.

Lacivita E, Patarnello D, Stroth N, Caroli A, Niso M, Contino M, et al. (2012). Investigations on the 1-(2-biphenyl)
piperazine motif: identification of new potent and selective ligands for the serotonin(7) (5-HT(7)) receptor with agonist or antagonist action in vitro or ex vivo. J Med Chem 55: 6375–6380.

Lemoine L, Andries J, Le Bars D, Billard T, Zimmer L (2011). Comparison of 4 radiolabeled antagonists for serotonin 5-HT (7) receptor neuroimaging: toward the first PET radiotracer. J Nucl Med 52: 1811–1818.

Leopoldo M, Berardi F, Colabufo NA, Contino M, Lacivita E, Niso M, et al. (2004a). Structure-affinity relationship study on N-(1,2,3,4-tetrahydroanaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxtryptamine7 receptor agents. J Med Chem 47: 4214–4221.

Leopoldo M, Lacivita E, De Giorgio P, Fracasso C, Guzzetti S, Caccia S, et al. (2008). Structural modifications of N-(1,2,3,4-tetrahydroanaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III. J Med Chem 51: 5813–5822.

Leopoldo M, Lacivita E, Berardi F, Perrone R, Heddlin PB (2011). Serotonin 5-HT7 receptor agents: structure-activity relationships and potential therapeutic applications in central nervous system disorders. Pharmacol Ther 129: 120–148.

Lovell PJ, Bromidge SM, Dabbs S, Duckworth DM, Forbes IT, Jennings AJ, et al. (2000). A novel, potent, and selective 5-HT (7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)(C19)-345. forskolin-stimulated adenylate cyclase by risperidone, 9-OH-risperidone and other “inactivating antagonists”. Mol Pharmacol 76: 552–559.

Tsao P, von Zastrow M (2000). Downregulation of G protein-coupled receptors. Curr Opin Neurobiol 10: 365–369.

Varin T, Gutiérrez-de-Terán H, Castro M, Brea J, Fabís F, Dauphin F, et al. (2010). Phe369(C19)/C19 inactivation of forskolin-stimulated adenylate cyclase by risperidone, 9-OH-risperidone and other “inactivating antagonists”. Mol Pharmacol 76: 552–559.

© 2013 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.